Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery
| 适应症 | Melanoma |
|---|---|
| 分期 | 2期 |
| 申办方 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
| 状态 | 已完成 |
| 受试者人数 | 26 人 |
| 干预（药物） | Nivolumab |
| 开始日期 | 2018年1月17日 |
| 完成日期 | 2025年12月15日 |
| 结果公布日 | 2026年6月16日 |
摘要
This phase II trial studies how well nivolumab works in treating patients with stage IIB-IIC melanoma that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.
Recurrence-free Survival
| Treatment (Nivolumab) | 87.8 percentage of participants |
|---|
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)